The First FDA Warning Letter Referencing AI: Why the Failure Was Not the Technology, but the Lack of Control
The first FDA Warning Letter explicitly referencing the use of Artificial Intelligence is making waves across the industry. But a closer look reveals: the failure was not the technology itself, but the lack of control around it. Missing validation, insufficient documentation, and poor process integration — the actual weaknesses are well-known GMP issues.
Warning Letter analyzed in detail